Health Care [ 3/12 ] | Biotechnology [ 9/75 ]
NASDAQ | Common Stock
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States.
The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity.
Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 12, 26 | -0.05 Increased by +44.32% | -0.13 Increased by +61.54% |
| Nov 13, 25 | -0.05 Increased by +41.11% | -0.12 Increased by +58.33% |
| Sep 29, 25 | -0.05 Increased by 0.00% | -0.05 |
| May 13, 25 | -0.04 Increased by +33.33% | -0.05 Increased by +20.00% |
| Feb 11, 25 | -0.09 Increased by +18.36% | -0.08 Decreased by -12.25% |
| Nov 12, 24 | -0.08 Increased by +15.10% | -0.05 Decreased by -69.80% |
| Sep 25, 24 | -0.05 Increased by +50.00% | -0.13 Increased by +61.54% |
| May 15, 24 | -0.06 Increased by +45.45% | -0.12 Increased by +50.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by N/A% | -2.00 M Increased by +18.82% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -2.16 M Increased by +1.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -2.14 M Decreased by -58.88% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -1.68 M Decreased by -1.37% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -2.46 M Increased by +9.36% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.20 M Increased by +11.29% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.35 M Increased by +45.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.65 M Increased by +40.90% | Decreased by N/A% Decreased by N/A% |